A Randomized, Open-label, Phase 3 Trial of A+AVD Versus ABVD as Frontline Therapy in Patients With Advanced Classical Hodgkin Lymphoma

Trial Profile

A Randomized, Open-label, Phase 3 Trial of A+AVD Versus ABVD as Frontline Therapy in Patients With Advanced Classical Hodgkin Lymphoma

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 10 Dec 2017

At a glance

  • Drugs Brentuximab vedotin (Primary) ; Bleomycin; Dacarbazine; Doxorubicin; Vinblastine
  • Indications Hodgkin's disease
  • Focus Registrational; Therapeutic Use
  • Acronyms ECHELON-1
  • Sponsors Takeda Oncology
  • Most Recent Events

    • 10 Dec 2017 According to the American Society of Hematology media release, results from this study were presented at the 59th American Society of Hematology (ASH) Annual Meeting and Exposition in Atlanta.
    • 10 Dec 2017 Results assessing efficacy and tolerability of brentuximab vedotin in combination with doxorubicin + vinblastine + dacarbazine versus doxorubicin + bleomycin + vinblastine + dacarbazine as first-line therapy in patients with advanced Hodgkin's lymphoma, were published in the New England Journal of Medicine.
    • 10 Dec 2017 Results published in a Takeda media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top